Potential Development of an Oral COVID-19l Vaccine
Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg
- Company secures next step to continue to build-out pipeline of assets.
- University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing pre-clinical studies for the prevention of coronavirus diseases, including COVID-19.
- Aeterna Zentaris to evaluate the University’s coronavirus vaccine platform technology including COVID-19 under an exclusive option agreement.
to evaluate a preclinical potential COVID-19 vaccine developed at the Julius-Maximilians-University Wuerzburg (the “University”), one of Germany’s leading research and teaching universities.
The vaccine technology developed at the University uses a typhoid fever vaccine as a carrier strain and has the potential to be an orally active COVID-19 (SARS-CoV-2) live-attenuated bacterial vaccine.
Under the option agreement entered into with the University, Aeterna has the right to negotiate an exclusive worldwide license to develop this technology for the prevention of coronavirus diseases, including COVID-19.
A scientific advice meeting with the German authorities at Paul-Ehrlich Institute has been scheduled by the University to discuss a roadmap towards initiating a first-in-human clinical trial.
finance.yahoo.com/news/aeterna-zentaris-announces-evaluation-potential-123000272.html
Aeterna expects to make a decision whether to exercise its option to negotiate a license for that technology by mid 2021.
- Company secures next step to continue to build-out pipeline of assets.
- University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing pre-clinical studies for the prevention of coronavirus diseases, including COVID-19.
- Aeterna Zentaris to evaluate the University’s coronavirus vaccine platform technology including COVID-19 under an exclusive option agreement.
to evaluate a preclinical potential COVID-19 vaccine developed at the Julius-Maximilians-University Wuerzburg (the “University”), one of Germany’s leading research and teaching universities.
The vaccine technology developed at the University uses a typhoid fever vaccine as a carrier strain and has the potential to be an orally active COVID-19 (SARS-CoV-2) live-attenuated bacterial vaccine.
Under the option agreement entered into with the University, Aeterna has the right to negotiate an exclusive worldwide license to develop this technology for the prevention of coronavirus diseases, including COVID-19.
A scientific advice meeting with the German authorities at Paul-Ehrlich Institute has been scheduled by the University to discuss a roadmap towards initiating a first-in-human clinical trial.
finance.yahoo.com/news/aeterna-zentaris-announces-evaluation-potential-123000272.html
Aeterna expects to make a decision whether to exercise its option to negotiate a license for that technology by mid 2021.
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.